Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Cancer Cell. 2019 Aug 12;36(2):119-121. doi: 10.1016/j.ccell.2019.07.005.
FOXA1 mutations occur frequently in prostate cancer and are associated with a worse clinical outcome. However, the mechanism by which these mutations act was until now largely unknown. Two recent publications clearly demonstrate that FOXA1 acts as an oncogene in prostate cancer and delineate the phenotypic effects of distinct classes of FOXA1 alterations.
FOXA1 突变在前列腺癌中频繁发生，并与更差的临床结局相关。然而，这些突变作用的机制在很大程度上至今仍未知。最近的两项研究明确表明，FOXA1 在前列腺癌中起致癌基因的作用，并描绘了不同类型 FOXA1 改变的表型效应。
